Kura Oncology's Darlifarnib-Cabozantinib Combo Shows Promise in Resistant Kidney Cancer
Event summary
- Kura Oncology reported preliminary data from the FIT-001 trial showing a 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib.
- Tumor shrinkage was observed in 75% of patients, with reductions ranging from 32% to 47% among responders.
- The FIT-001 study is evaluating darlifarnib in combination with cabozantinib in patients with RCC who have received prior immunotherapy.
- Kura Oncology hosted a virtual investor event on April 17, 2026, to discuss the findings.
The big picture
Kura Oncology's findings suggest a potential breakthrough in treating resistant clear cell renal cell carcinoma (ccRCC), a population with limited treatment options. The combination of darlifarnib and cabozantinib could address mechanisms of resistance and enhance the activity of VEGFR-targeted therapies, positioning Kura in the competitive landscape of precision oncology. The results align with broader industry trends toward combination therapies and overcoming drug resistance in cancer treatment.
What we're watching
- Clinical Validation
- How the robust activity of darlifarnib plus cabozantinib in resistant ccRCC patients will impact future clinical trials and regulatory approvals.
- Market Differentiation
- Whether Kura Oncology can position darlifarnib as a key player in overcoming resistance to VEGF TKI therapies in the competitive oncology market.
- Execution Risk
- The pace at which Kura Oncology can advance the combination therapy through Phase 1b dose expansion and into later-stage trials.
Related topics